Format
Sort by
Items per page

Send to

Choose Destination

Best matches for OXYCODONE/AE:

Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Burness CB et al. Drugs. (2014)

Oxycodone for neuropathic pain and fibromyalgia in adults. Gaskell H et al. Cochrane Database Syst Rev. (2014)

Oxycodone for cancer-related pain. Schmidt-Hansen M et al. Cochrane Database Syst Rev. (2015)

Search results

Items: 1 to 20 of 639

1.

Oxycodone/naloxone in postoperative pain management of surgical patients.

Gkegkes ID, Minis EE, Iavazzo C.

J Opioid Manag. 2018 Jan/Feb;14(1):52-60. doi: 10.5055/jom.2018.0429. Review.

PMID:
29508896
2.

Effect of oxycodone hydrochloride combined with flurbiprofen axetil for intravenous patient-controlled analgesia in lower abdominal patients: A randomized trial.

Xiang X, Yuan X, Lian Y, Fang J, Wu Y.

Medicine (Baltimore). 2018 Feb;97(7):e9911. doi: 10.1097/MD.0000000000009911.

3.

Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.

Setnik B, Schoedel K, Bartlett C, Dick C, Hakim N, Geoffroy P.

J Opioid Manag. 2017 Nov/Dec;13(6):449-464. doi: 10.5055/jom.2017.0421.

PMID:
29308591
4.

Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.

Cassidy TA, Thorley E, Black RA, DeVeaugh-Geiss A, Butler SF, Coplan P.

J Opioid Manag. 2017 Nov/Dec;13(6):425-440. doi: 10.5055/jom.2017.0419.

PMID:
29308589
5.

Prolonged-Release Oxycodone/Naloxone Improves Anal Sphincter Relaxation Compared to Oxycodone Plus Macrogol 3350.

Poulsen JL, Brock C, Grønlund D, Liao D, Gregersen H, Krogh K, Drewes AM.

Dig Dis Sci. 2017 Nov;62(11):3156-3166. doi: 10.1007/s10620-017-4784-7. Epub 2017 Oct 6.

PMID:
28986667
6.

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).

Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Terashima M, Yoshida T, Sakai K, Otake Y, Koyama A, Nishio K, Nakagawa K.

BMC Cancer. 2017 Oct 6;17(1):674. doi: 10.1186/s12885-017-3664-z.

7.

Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
.

Scheidel B, Maritz MA, Gschwind YJ, Steigerwald K, Guth V, Kovacs P, Rey H.

Int J Clin Pharmacol Ther. 2017 Nov;55(11):881-890. doi: 10.5414/CP203005.

8.

A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.

Nosek K, Leppert W, Nosek H, Wordliczek J, Onichimowski D.

Drug Des Devel Ther. 2017 Aug 22;11:2409-2419. doi: 10.2147/DDDT.S141007. eCollection 2017.

9.

Spasmolytic Mechanism of Aqueous Licorice Extract on Oxytocin-Induced Uterine Contraction through Inhibiting the Phosphorylation of Heat Shock Protein 27.

Yang L, Chai CZ, Yan Y, Duan YD, Henz A, Zhang BL, Backlund A, Yu BY.

Molecules. 2017 Aug 29;22(9). pii: E1392. doi: 10.3390/molecules22091392.

10.

Oxycodone for cancer-related pain.

Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS.

Cochrane Database Syst Rev. 2017 Aug 22;8:CD003870. doi: 10.1002/14651858.CD003870.pub6. Review.

PMID:
28829910
11.

Oxycodone-induced neurotoxicity secondary to concurrent voriconazole use in a patient with cancer.

Alghothani L, Gustin J.

J Opioid Manag. 2017 May/Jun;13(3):141-142. doi: 10.5055/jom.2017.0381.

PMID:
28829515
12.

Effects of oxycodone on immune function in patients undergoing radical resection of rectal cancer under general anesthesia.

Cui JH, Jiang WW, Liao YJ, Wang QH, Xu M, Li Y.

Medicine (Baltimore). 2017 Aug;96(31):e7519. doi: 10.1097/MD.0000000000007519.

13.

Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Huang L, Zhou JG, Zhang Y, Wang F, Wang Y, Liu DH, Li XJ, Lv SP, Jin SH, Bai YJ, Ma H.

J Pain Symptom Manage. 2017 Nov;54(5):737-748.e3. doi: 10.1016/j.jpainsymman.2017.07.025. Epub 2017 Jul 21. Review.

PMID:
28736104
14.

Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone.

Robson KJ, Clucas D, Filshie R, Nandurkar H.

BMJ Case Rep. 2017 Jul 17;2017. pii: bcr-2017-220977. doi: 10.1136/bcr-2017-220977.

PMID:
28716778
15.

Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.

Haeseler G, Schaefers D, Prison N, Ahrens J, Liu X, Karch A.

BMC Anesthesiol. 2017 Jul 11;17(1):91. doi: 10.1186/s12871-017-0383-6.

16.

The analgesic efficacy of oxycodone hydrochloride versus fentanyl during outpatient artificial abortion operation: A randomized trial.

Xie K, Zhang W, Fang W, Lian Y, Lin S, Fang J.

Medicine (Baltimore). 2017 Jun;96(26):e7376. doi: 10.1097/MD.0000000000007376.

17.

Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.

Vosburg SK, Haynes C, Besharat A, Green JL.

Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1044-1052. doi: 10.1002/pds.4248. Epub 2017 Jun 27.

PMID:
28653782
18.

Clinical pearls in pulmonary diseases.

Daniels CE, Litin SC, Bundrick JB.

Dis Mon. 2017 Jun;63(6):141-148. doi: 10.1016/j.disamonth.2017.03.012. No abstract available.

PMID:
28651690
19.

The effects of analgesics on central processing of tonic pain: A cross-over placebo controlled study.

Lelic D, Hansen TM, Mark EB, Olesen AE, Drewes AM.

Neuropharmacology. 2017 Sep 1;123:455-464. doi: 10.1016/j.neuropharm.2017.06.022. Epub 2017 Jun 22.

PMID:
28648913
20.

A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.

Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, Hopp M.

Eur J Pain. 2017 Oct;21(9):1528-1537. doi: 10.1002/ejp.1054. Epub 2017 Jun 22.

Supplemental Content

Loading ...
Support Center